ArticleEuropean heart journal open2024
New data allow to better understand the secrets of lipoprotein(a): is that for sure?
Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis.Current atherosclerosis reports · 2025Pooled it
- Lipoprotein(a) levels in Finnish adults: distribution and associations with other cardiovascular risk factors and their awareness and control.Lipids in health and disease · 2026Article
- The CARDIOLIPID Plan: A Cardiovascular Risk-centred Implementation Framework for the Diagnosis and Management of Dyslipidaemia: Experts' Proposal.European cardiology · 2026Review
- Cardiovascular risk burden and guideline-recommended lipid and blood pressure goals in an Italian Cohort: findings from the HUMTELEMED web-based platform.BMC medicine · 2025Article
- Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years.Lipids in health and disease · 2025Article
- Superior prognostic value of estimated small dense LDL cholesterol for cardiovascular risk assessment: evidence from international cohort studies.Lipids in health and disease · 2025Article
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
- Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.Archives of medical science : AMS · 2025Article
- Treatment of dyslipidemia in Poland - common diagnostics, early combined therapy. Expert position statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. 5th Declaration of Sopot.Cardiology journal · 2025Article
- Intervention, improved prevention, imaging, inflammation, and innovation: the five I's cardiovascular highlights inEuropean heart journal open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.